Skip to main content
Keytruda, Inlyta combo shows benefits for kidney cancer patients

Statistically meaningful improvements in overall survival and disease progression were seen in patients with kidney cancer treated with a combination of Merck's Keytruda, or pembrolizumab, and Pfizer's Inlyta, or axitinib. The combination treatment met the main goals of the late-stage trial as compared with kidney cancer drug Sutent, or sunitinib malate, also from Pfizer.

Full Story: